BioCrea GmbH
BioCrea GmbH: BioCrea’s Anti Depression Program Voted Top Neuroscience Project to Watch
BioCrea GmbH / Key word(s): Conference BioCrea’s Anti Depression Program Voted “Top Neuroscience Project to Watch” BioCrea invited to present NMDA NR2B NAM program at the Therapeutic Area Partnerships meeting on November 19-21, 2014 in Boston Radebeul, Germany, November 18, 2014 – BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that the Company’s NMDA NR2B NAM program has been chosen as one of the “Top Neuroscience Projects to Watch” by Informa’s IN VIVO, Start-up and The Pink Sheet. The NMDA NR2B small molecule program is currently being developed to treat Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD). BioCrea has been invited to present the project at the Therapeutic Area Partnerships (TAP) meeting, which takes place on November 19-21, 2014 in Boston, USA: Session: Track 1: Neuroscience “Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider to be the most attractive opportunities the industry has to offer,” said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. “As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners and acquirers.” The “Top Neuroscience Projects to Watch” have been chosen by independent industry experts. BioCrea met the selection criteria, which included: an unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.
About the Therapeutic Area Partnerships (TAP) Attendees have the opportunity to hear from and meet some of the industry’s most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry’s most productive events. Contact Dr. Tom Kronbach 18.11.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
297721 18.11.2014 |